A 28-year-old female from Delhi with newly diagnosed sputum smear-positive pulmonary TB is enrolled in RNTCP. She is 8 weeks into Category 1 treatment (HRZE) and reports good adherence. Her repeat sputum smear microscopy at 2 months shows conversion to smear-negative status. However, she now presents with fever, jaundice, and right upper quadrant tenderness. Liver function tests show ALT 320 U/L, AST 280 U/L, bilirubin 4.2 mg/dL. What is the most appropriate management according to NTEP guidelines?

Explanation

## Management of Drug-Induced Hepatotoxicity in TB Treatment **Key Point:** Drug-induced liver injury (DILI) during anti-TB therapy requires temporary discontinuation of hepatotoxic agents, monitoring of LFTs, and careful re-introduction once liver function normalizes. The decision to restart and which drugs to use depends on the severity of hepatotoxicity and clinical status. ### Classification of TB-DILI Severity | Severity | ALT/AST (U/L) | Bilirubin (mg/dL) | Clinical Features | Management | | --- | --- | --- | --- | --- | | **Mild** | <5× ULN | <2 | Asymptomatic | Monitor, continue if asymptomatic | | **Moderate** | 5–10× ULN | 2–5 | Mild symptoms (nausea, RUQ pain) | Stop drugs, monitor, restart after normalization | | **Severe** | >10× ULN | >5 | Jaundice, encephalopathy, coagulopathy | Stop drugs, intensive monitoring, consider alternative regimen | **High-Yield:** This patient has moderate-to-severe hepatotoxicity (ALT 320, bilirubin 4.2) with clinical signs (jaundice, RUQ tenderness). NTEP guidelines recommend **temporary discontinuation** until LFTs normalize to <3× ULN. ### NTEP Algorithm for TB-DILI Management ```mermaid flowchart TD A[Suspected TB-DILI]:::outcome --> B[Check LFTs and bilirubin]:::action B --> C{Severity?}:::decision C -->|Mild, asymptomatic| D[Continue treatment, monitor LFTs]:::action C -->|Moderate with symptoms| E[Stop all hepatotoxic drugs]:::action C -->|Severe| F[Stop all drugs, ICU monitoring]:::urgent E --> G[Monitor LFTs weekly]:::action G --> H{LFTs normalize?}:::decision H -->|Yes| I[Restart with modified regimen]:::action H -->|No| J[Extend monitoring, consider alternatives]:::action I --> K{Which drugs to restart?}:::decision K -->|If INH/RIF suspected| L[Start with ethambutol + fluoroquinolone]:::action K -->|If pyrazinamide suspected| M[Use HRE or HRF regimen]:::action ``` ### Hepatotoxicity Risk by Drug **High-risk drugs (in order of frequency):** 1. **Isoniazid (INH)** — most common cause (~1–2% of patients) 2. **Rifampicin (RIF)** — less common but more severe when occurs 3. **Pyrazinamide (PZA)** — dose-dependent, risk increases with higher doses 4. **Ethambutol (EMB)** — rarely hepatotoxic 5. **Streptomycin (SM)** — rarely hepatotoxic **Clinical Pearl:** In this case, the hepatotoxicity is most likely due to INH or RIF (the most hepatotoxic agents in Category 1 regimen). Temporary discontinuation is safer than continuing with hepatoprotective agents alone, which have limited evidence. ### Management Steps 1. **Immediate action:** Stop all anti-TB drugs 2. **Monitoring:** Check LFTs weekly until ALT/AST <3× ULN and bilirubin <2 mg/dL 3. **Restart protocol:** - Start with **ethambutol + fluoroquinolone** (least hepatotoxic combination) - After 2 weeks of tolerance, add **rifampicin** (if RIF not the culprit) - After another 2 weeks, add **isoniazid** (if INH not the culprit) - Restart **pyrazinamide** last or use lower dose **Warning:** Continuing the same regimen with hepatoprotective agents is NOT recommended by NTEP because: - Hepatoprotective agents (silymarin, ursodeoxycholic acid) lack robust evidence in TB-DILI - Continued exposure to hepatotoxic drugs may cause acute liver failure - Temporary discontinuation is safer and allows liver recovery **High-Yield Mnemonic — TB-DILI Management: STOP-MONITOR-RESTART** - **S** = Stop hepatotoxic drugs immediately - **T** = Test LFTs weekly - **O** = Observe for clinical improvement - **P** = Plan re-introduction with least hepatotoxic agents first - **M** = Monitor during re-introduction - **O** = Optimize regimen based on tolerance - **N** = Note which drug caused DILI for future reference - **I** = Introduce remaining drugs sequentially - **T** = Track LFTs until normalized - **O** = Observe for recurrence - **R** = Restart full regimen once all drugs tolerated - **A** = Adjust future TB treatment if needed - **R** = Review adherence and drug interactions - **T** = Total treatment duration may extend beyond 6 months [cite:NTEP Guidelines 2023, Harrison 21e Ch 158]